Benzinga··Vandana SinghRevolution Medicines Soars 40% on Pancreatic Cancer Breakthrough, Despite Merck Deal Collapse
Revolution Medicines surges 40% after Phase 3 trial shows daraxonrasib doubles survival in metastatic pancreatic cancer versus chemotherapy.
MRKRVMDRVMDWPhase 3 trialclinical trial results